Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

real-world data

This page shows the latest real-world data news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

The company is looking to reassure doctors and patients about the safety of Invokana, and recently  revealed real-world data that found no amputation risk for the drug - but this safety ... However, the new safety data, coupled with the new phase 3

Latest news

  • FDA and Flatiron extend real world evidence collaboration FDA and Flatiron extend real world evidence collaboration

    These data, which included real-world endpoints such as progression, tumour response and reason for therapy discontinuation, supported a number of novel outcomes research projects. ... We believe that regulatory-grade real-world data can help inform our

  • Greater Manchester backs move to outcome-based payment Greater Manchester backs move to outcome-based payment

    Also of central importance is the need to build robust data collection and real world evidence systems. ... The big challenge in realising this vision is having a nationwide digital system to collect all the relevant clinical data.

  • Going digital Going digital

    How will developers ensure that patients’ data is secure from external access and use? ... Equally, the rise. of big data – the combination of data collected about and by the patient – has the potential to be a treasure trove of real-world data if

  • Big opportunities in big data, but EMA and industry just getting started Big opportunities in big data, but EMA and industry just getting started

    Big data encompasses a broad range of non-clinical trial sources, from emerging ‘omics’ (genomics, proteomics etc) as well as electronic patient records, real world studies and patient-generated data from ... Europe’s efforts mirror similar

  • Novartis forges AI alliance with Oxford University Novartis forges AI alliance with Oxford University

    old project with IBM Watson Health applying AI to real-world data to improve insight on the expected outcomes of breast cancer treatment. ... converting and mapping raw data to make it more suitable for specific tasks – and Oxford University’s

More from news
Approximately 13 fully matching, plus 89 partially matching documents found.

Latest Intelligence

  • Why precision medicine demands precision engagement Why precision medicine demands precision engagement

    Real-world data from patient records is also growing rapidly. Treatment teams need to remain current on both the latest advances and real-world patient outcomes, while also contributing their own ... Through this technology-supported approach, life

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Changes in approach in the US, EU and China are driving more parallel studies, more accelerated approvals and the accumulation of more real-world evidence for additional indications. ... Innovators are increasingly incorporating these health economics

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    data. The importance of real-world data is growing rapidly, but its quality, taxonomy and accessibility are not standardised and once again require collaboration to pull it off. ... An example is the real-world observational study GSK conducted for its

  • Brand teams: why are some smarter than others? Brand teams: why are some smarter than others?

    Although life sciences companies talk about having world-class commercial teams, the truth is rather more mundane. ... 3.  Testing, when the hypotheses developed from the explicated assumptions are tested against real-world data.

  • Reaching the new influencers Reaching the new influencers

    With payers looking increasingly to  real-world data,   and to differentiation beyond this data through outcomes commitment and the provision of beyond the pill services, there’s never been a ... The growth in availability and importance of

More from intelligence
Approximately 6 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Astellas appoints new senior VP Astellas appoints new senior VP

    pioneered multiple real-world data endeavours and built research partnerships with academic and managed care organisations.

  • Dr Ameet Nathwani moves from Novartis to Sanofi Dr Ameet Nathwani moves from Novartis to Sanofi

    Oliver Brandicourt, Sanofi's chief executive officer, said: “Our industry is experiencing increased pressure to support reimbursement with customized data from real-world evidence, demonstrate ongoing benefit-risk of registered products

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Infographic: Rheumatoid arthritis (RA)

    An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. ... The snapshot looks at twelve of the key indices captured in Therapy Watch data.

  • NHS medicines optimisation milestone

    This targeted and granular data can be cross referenced from multiple health and social care sources. ... Other useful real-world data includes diagnostic imaging datasets and prescribing data from NHS Digital, which delves down to GP surgery level.

  • Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?

    You might think this is a naïve question. It feels like it is, but if this is the case, why do marketers, brand builders, creatives and communicators from the consumer world ... formulated from third party, real world evidence and peer reviewed data.

  • VR/AR - Dr Tim Ringrose

    Data from patients provides highly valuable real world insight into compliance issues, unmet needs and patient satisfaction. .

  • Three key development areas in the management of multiple sclerosis

    Clinical trial and real-world data supporting the efficacy of disease-modifying therapies in newly diagnosed and early MS were presented at the ECTRIMS congress. ... The data showed that the majority of patients remained free from confirmed disability

More from PMHub
Approximately 1 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia